Narnatumab is under investigation in clinical trial NCT01119456 (A Study of IMC-RON8 in Advanced Solid Tumors).
货号（Catalog No.）
CSD00263
通用名INN
Narnatumab
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Narnatumab is under investigation in clinical trial NCT01119456 (A Study of IMC-RON8 in Advanced Solid Tumors).
别名(Alternative names)
IMC RON-8,RON8
靶点;物种(Specificity target name;species)
MST1R/CD136[Homo sapiens]
活性研究（体外/体内研究）(Activity in vitro)
LY2801653 demonstrates in vitro effects on MET pathway-dependent cell scattering and cell proliferation. It demonstrates more potent anti-proliferative activity in cell lines with MET gene amplification (MKN45, Hs746T and H1993) than the cell lines without MET gene amplification (U-87MG, KATO-III). LY2801653 also maintains potency against 13 MET variants, each bearing a single-point mutation. It is found to have potent activity against several other receptor tyrosine oncokinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, DDR1/2 and against the serine/threonine kinases MKNK1/2. The mean IC50 value of LY2801653 for inhibition of MET auto-phosphorylation in HGF-stimulated H460 cells is 35.2±6.9 nM and the IC50 for MET auto-phosphorylation in S114 cells is 59.2 nM.
种类(Species)
Homo sapiens
受体鉴定(Receptor identification)
IgG1-kappa
化学信息
CAS
1188275-92-4
存储条件(Storage)
store at -80°C

Note
For research use only. Not suitable for clinical or therapeutic use.